Clinical trial
A Randomized, Double-Blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT002 in Healthy Volunteers and Participants With Chronic Obstructive Pulmonary Disease (COPD)
NCT07288554 is registered in ClinicalTrials.gov with Bambusa Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT002 in Healthy Volunteers and Participants With Chronic Obstructive Pulmonary Disease (COPD)
- Lead sponsor
- Bambusa Therapeutics
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- September 5, 2025
- Completion date
- May 30, 2027
- Enrollment
- 68 (estimated)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.
chronic obstructive pulmonary disease (copd)